GPGA
ENTA icon

Grandeur Peak Global Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Grandeur Peak Global Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,600
Closed -$64K – 115
2014
Q1 		$64K Hold
1,600
– – 0.02% 107
2013
Q4 		$44K Buy
1,600
+350
+28% +$8.48K 0.01% 110
2013
Q3 		$29K Buy
1,250
+950
+317% +$18.2K 0.01% 124
2013
Q2 		$5K Buy
+300
New +$5.85K ﹤0.01% 118

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICRM
Insight Capital Research & Management Walnut Creek, California $177M AUM 72% 1-Year Est. Return

Grandeur Peak Global Advisors's ENTA Position: Q2 2014 in Review

Grandeur Peak Global Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2014, closing a stake of 1,600 shares — an estimated $64K sold.

Grandeur Peak Global Advisors first reported a position in ENTA in Q2 2013 and held it in 4 quarters. The position peaked at $64K in Q1 2014. 98 funds tracked by Wall St. Rank hold ENTA as of Q2 2014.

  • Grandeur Peak Global Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Grandeur Peak Global Advisors sold 1,600 Enanta Pharmaceuticals shares in Q2 2014, an estimated $64K.
  • Grandeur Peak Global Advisors first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Grandeur Peak Global Advisors's Enanta Pharmaceuticals position peaked at $64K in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2014.

Based on Grandeur Peak Global Advisors's 13F filing for Q2 2014, filed 15 Aug 2014.